Edition:
United Kingdom

Grifols SA (GRLS.MC)

GRLS.MC on Madrid SE C.A.T.S.

24.71EUR
1:31pm BST
Change (% chg)

€0.30 (+1.23%)
Prev Close
€24.41
Open
€24.50
Day's High
€24.73
Day's Low
€24.39
Volume
167,003
Avg. Vol
648,422
52-wk High
€28.07
52-wk Low
€21.57

About

Grifols SA is a Spain-based company engaged in the biopharmaceuticals manufacture. The Company’s activities are divided into four business segments: Bioscience, Hospital, Diagnostic and Raw materials. The Bioscience division focuses on the research, development, manufacturing and marketing of products derived from human plasma... (more)

Overall

Beta: 0.59
Market Cap(Mil.): €14,861.74
Shares Outstanding(Mil.): 687.55
Dividend: 0.20
Yield (%): 1.24

Financials

  GRLS.MC Industry Sector
P/E (TTM): 28.03 59.33 59.93
EPS (TTM): 0.87 -- --
ROI: 5.75 12.26 11.86
ROE: 15.19 13.41 12.88

Spain's Grifols, China's Shanghai RAAS form strategic alliance

Spanish blood products company Grifols said on Thursday it has signed a strategic alliance with Shanghai RAAS as it looks to increase its sales of plasma-derived products in China.

07 Mar 2019

Spain's Grifols, China's Shanghai RAAS form strategic alliance

March 7 Spanish blood products company Grifols said on Thursday it has signed a strategic alliance with Shanghai RAAS as it looks to increase its sales of plasma-derived products in China.

07 Mar 2019

BRIEF-Grifols Says AMBAR Results Show Reduction In Progression of Moderate Alzheimer's Disease

* SAID ON SATURDAY THAT AMBAR CLINICAL TRIAL DEMONSTRATED THE ABILITY TO SLOW DOWN THE PROGRESSION OF THE DISEASE IN MODERATE ALZHEIMER'S DISEASE (AD) PATIENTS

29 Oct 2018

Earnings vs. Estimates